The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Sylvester, Dana-Farber researchers receive $7M from PCORI to study diet, exercise effects on mental and physical functioning in older cancer survivors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Dana Farber Cancer Institute have received $7 million from the Patient-Centered Outcomes Research Institute to study how diet and exercise impact mental and physical functioning in older cancer survivors and their caregivers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account